Resistance Training on Growth Factors

Acute Effect of Resistance Training With Different Intensity on Circulating Levels of Neurotrophic Growth Factors and Homocysteine in Young Adults

The goal of this clinial trial study is to explore the effect of high or low intensity resistance training (LIRT) under similar training volume on change in serum levels of BDNF, IGF-1, VEGF, irisin, and plasma Hcy in young adults.The main questions it aims to answer are:

1. Whether high and low intensity will increase the serum levels of BDNF, IGF-1, VEGF, irisin, and reduce plasma Hcy.
2. whether a greater magnitude of change would be suffer in low intensity group when compared to high intensity group, as an effect of greater physiological adaptation produced by more repetitions required to complete.

Participants will performe two different intensity resistance training (HIRT, at 80%1RM with 12 repetitions and 4-5 sets and LIRT, at 40%1RM with 24 repetitions and 4-5 sets).

Researchers will compare the training effects of two different training on these growth factors.

Study Overview

• Status: Not yet recruiting
• Conditions: Cognitive Function
• Intervention / Treatment: Other: High intensity resistance training; Other: Low intensity resistance training

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Chongwen Zuo, Doctoral; Phone Number: +86 18810716505; Email: zuochongwen@cupes.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• age between 18 to 30 years
• no experiencing musculoskeletal disorders or sports injuries
• had not participated any regular aerobic endurance or resistance training with in the previous half years
• no smoking habit or intake alcohol and other medication (e.g., steroid hormone)
• good general body condition without any chronic diseases (e.g., osteoarthritis, metabolic syndrome or arthritis)

Exclusion Criteria:

• experiencing musculoskeletal disorders or sports injuries in recent 1 month
• had regular resistance training exercise
• intake any supplementary(drug and hormone)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: High-intensity resistance training group (HIRT); All subjects were instructed to conduct HIRT consisted of 4-5 sets of 12 repetitions at 80%1RM, with 1-2 minutes rests between each set.	Other: High intensity resistance training; The HIRT protocol comprised five exercises (bench press, barbell back squat, deadlift, seated leg flexion, and reverse arm curl) at 80% of 1RM, and 4-5 sets of 12 repetitions with 1-2 minutes of rest period between sets for approximately 60 minutes.
Experimental: low-intensity resistance training group (LIRT); All subjects were instructed to conduct LIRT consisted of 4-5 sets of 24 repetitions at 40%1RM, with same period) in random order.	Other: Low intensity resistance training; For LIRT protocol, which performed same training exercises as HIRT. The repetitions in the LIRT protocol were assessed using the following equation: 80% of 1RM lifting load (kg) ×repetitions (HIRT)/40% of 1RM to volition fatigue, with 1-2 minutes of rest period between sets. Therefore, the LIRT protocol completed 4-5 sets of 24 repetitions at 40% of 1RM for a total of 60 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rata of perceived exertion	The rating of perceive exertion (RPE) questionnaire scale was applied to assess participants' subjective fatigue feeling throughout the training period.	"0 minutes" "60 minutes" "90 minutes"
Blood lactate	serum blood lactate	"0 minutes" "60 minutes" "90 minutes"
BDNF	regulators of neurogenesis	"0 minutes" "60 minutes" "90 minutes"
IGF-1	regulators of neurogenesis	"0 minutes" "60 minutes" "90 minutes"
VEGF	regulators of neurogenesis	"0 minutes" "60 minutes" "90 minutes"
Irisin	regulators of neurogenesis	"0 minutes" "60 minutes" "90 minutes"
Hcy	homocysteine (Hcy) increase with age and resulted in cognitive function decline through greater oxidative stress and vascular dysfunction	"0 minutes" "60 minutes" "90 minutes"

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reactive time	Reaction time is the time it takes for the body to go from receiving a stimulus to responding to an action	"0 minutes" "60 minutes" "90 minutes"
Accuracy rate	Accuracy refers to the correct degree of expression or description of a thing, which is used to reflect the correct answer to the thing	"0 minutes" "60 minutes" "90 minutes"

Collaborators and Investigators

• Sponsor: Air Force Military Medical University, China
• Investigators: Principal Investigator: Chongwen Zuo, Doctoral, Air Force Medical Center of Chinese PLA

Study record dates

Study Major Dates

• Study Start (Estimated): February 27, 2024
• Primary Completion (Estimated): March 30, 2024
• Study Completion (Estimated): April 7, 2024

Study Registration Dates

• First Submitted: October 24, 2023
• First Submitted That Met QC Criteria: October 27, 2023
• First Posted (Actual): November 2, 2023

Study Record Updates

• Last Update Posted (Estimated): February 1, 2024
• Last Update Submitted That Met QC Criteria: January 30, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: VEGF; BDNF; Irisin; IGF-1; neurotrophic growth factors; Hcy
• Other Study ID Numbers: zuochongwen

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher. First author should be contacted if someone wants to request the data from this study.
• IPD Sharing Time Frame: When this study was published.
• IPD Sharing Access Criteria: Shall not be used for secondary analysis or repeated publication
• IPD Sharing Supporting Information Type: SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No